跳至主要内容
临床试验/CTRI/2010/091/002959
CTRI/2010/091/002959尚未招募3 期

Phase III randomized controlled trial of Image Guided Intensity Modulated Radiotherapy (IG-IMRT) and Conventional Radiotherapy for late toxicity reduction reduction after postoperative radiotherapy in carcinoma cervix.

il0 个研究点目标入组 240 人开始时间: 待定最近更新:

试验速览

阶段
3 期
状态
尚未招募
发起方
入组人数
240

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1.Histopathological diagnosis of carcinoma cervix with postoperative intermediate or high risk features.
  • 2.Age > 18 years
  • 3.Planned for Wertheim's hysterectomy or has already undergone simple hysterectomy and has no evidence of residual pelvic nodes on MRI/PET imaging +/_ confirmatory nodal biopsy.
  • 4.No evidence of paraaortic nodal biopsy.
  • 5.WIlling for specimen archiving in tumor tissue biorepository.

排除标准

  • 1.History of multiple previous abdominal surgeries placing patient at baseline high risk of bowel toxicity or any other medical condition with baseline bowel movement disorder.
  • 2.Rectal Polyps or extensive hemorroids causing bleeding.

研究者

发起方
il

相似试验

招募中
3 期
A clinical trial to compare toxicity reduction between image guided intensity modulated radiotherapy (IG-IMRT) and conventional radiotherapy in Cancer Cervix (PARCER) patients.
CTRI/2012/12/003249Tata Memorial Centre240
已完成
不适用
Phase I/II clinical trial of stereotactic body radiotherapy in patients with cervical cancer who are unsuitable for intracavitary brachytherapyterine cervical cancer
JPRN-UMIN000036845Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital21
进行中(未招募)
不适用
The Positive Choices trial of a social marketing intervention to promote sexual health and reduce health inequalities among English secondary school studentsSexual health
ISRCTN16723909ondon School of Hygiene & Tropical Medicine6,970
进行中(未招募)
1 期
Phase III randomized, placebo controlled study of sorafenib in repeated cycles of 21 days in combination with paclitaxel/carboplatin chemotherapy in subjects with unresectable stage III or stage IV melanomaunresectable, advanced Stage III or Stage IV melanoma
EUCTR2005-000941-12-DEOnyx Pharmaceuticals, Inc.
进行中(未招募)
1 期
A randomised Phase III trial to evaluate the efficacy of chemoimmunotherapy with the monoclonal antibody Campath-1H (Alemtuzumab) given in combination with 2-weekly CHOP (Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) versus 2-weekly CHOP alone in elderly patients with previously untreated systemic T- cell Lymphoma Short Title: A-CHOP-14 (elderly) - A-CHOP-14 (elderly)Primary therapy of patients with Alk-negative T-NHL in patients aged 61 - 80 yearsICD classification codes : ICD-O 9702/39717/39716/39708/39705/39714/3MedDRA version: 9.1Level: LLTClassification code 10002464Term: Angiomimmunoblastic (AILD, LgX (Kiel Classification)MedDRA version: 9.1Level: LLTClassification code 10025632Term: Malignant lymphoma
EUCTR2007-000821-23-BEniversity Medicine Goettingen274